Implementation of changes to Medicare payment for clinical laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Duration: October 6, 2015
to
August 31, 2018
General Issues: Medicare/Medicaid , Medical/Disease Research/Clinical Labs
Spending: about $290,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John (Kevin) Brennan
Chief of Staff, Rep. Rosa DeLauro (D-CT); Legislative Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2018
Faegre Baker Daniels Consulting terminated an engagement in which they represented Myriad Genetic Laboratories, Inc. on Sept. 7, 2018.
Original Filing: 300981541.xml
Lobbying Issues
Implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2018
In Q2, Faegre Baker Daniels Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300973212.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2018
In Q1, Faegre Baker Daniels Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on April 18, 2018.
Original Filing: 300948041.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2017
In Q4, Faegre Baker Daniels Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on Jan. 18, 2018.
Original Filing: 300927352.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2017
In Q3, Faegre Baker Daniels Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300912094.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2017
In Q2, Faegre Baker Daniels Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300889587.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2017
In Q1, Faegre Baker Daniels Consulting (f/k/a FaegreBD Consulting) lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on April 19, 2017.
Original Filing: 300869057.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2016
In Q4, FaegreBD Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $15,000. The report was filed on Jan. 23, 2017.
Original Filing: 300854571.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
3rd Quarter, 2016
In Q3, FaegreBD Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $15,000. The report was filed on Oct. 14, 2016.
Original Filing: 300828026.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
2nd Quarter, 2016
In Q2, FaegreBD Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300820423.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
1st Quarter, 2016
In Q1, FaegreBD Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $20,000. The report was filed on April 19, 2016.
Original Filing: 300796160.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
In Q4, FaegreBD Consulting lobbied for Myriad Genetic Laboratories, Inc. , earning $10,000. The report was filed on Jan. 20, 2016.
Original Filing: 300778331.xml
Lobbying Issues
PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
FDA draft guidance to regulate laboratory developed tests and companion diagnostics. Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
4th Quarter, 2015
FaegreBD Consulting filed a lobbying registration on Dec. 22, 2015 to represent Myriad Genetic Laboratories, Inc., effective Oct. 6, 2015.
Original Filing: 300768560.xml
Issue(s) they said they’d lobby about: PL 113-93 (HR 4302) - Protecting Access to Medicare Act of 2014; implementation of changes to Medicare payment for clinical laboratory tests.
FDA draft guidance to regulate laboratory developed tests and companion diagnostics
Legislation to further regulate clinical labs under CLIA and FDA (legislation not yet introduced; discussion draft only - no HR #) .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate